Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2022-03-09 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
2021年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2021 年年度报告全文" (2021 Annual Report Full Text) of 普洛药业股份有限公司 (Apeloa Pharmaceutical Co., Ltd). It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, and financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial data, management discussion, and comprehensive company information for the fiscal year 2021. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-03-09 Chinese
关于补选公司独立董事的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding the nomination and election of a new independent director to the company's board. It references compliance with company law, securities law, and stock exchange listing rules. The content focuses on board/management changes, specifically the nomination and approval process for a new independent director. There is no financial data, no report publication, no voting results, and no other regulatory or financial disclosures. Therefore, this document fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2022-03-09 Chinese
股东大会议事规则
Governance Information Classification · 95% confidence The document is titled as "股东大会议事规则" which translates to "Rules of Procedure for the Shareholders' General Meeting" of 普洛药业股份有限公司. It details the procedures, powers, and regulations governing the conduct of the shareholders' meetings, including the rights and responsibilities of shareholders, the process for convening meetings, voting procedures, and announcement requirements. It is a governance document outlining internal rules and practices related to shareholder meetings rather than an announcement of a meeting, voting results, or a report of financial or operational performance. It does not contain financial statements or earnings data, nor is it a transcript or presentation. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-03-09 Chinese
关于公司第一期员工持股计划存续期展期的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the extension of the duration of the company's first employee stock ownership plan. It details board resolutions, shareholder meetings, and independent director opinions related to this employee stock plan extension. There are no financial statements, earnings data, or regulatory certifications. The document is a formal announcement about a corporate governance and employee stock plan matter, not a full report or financial filing. It fits best under Regulatory Filings (RNS) as it is a regulatory announcement about corporate actions that do not fall under other specific categories.
2022-03-09 Chinese
独立董事对担保等事项的独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by the independent directors of the company regarding the use of company funds by controlling shareholders and related parties, as well as the company's external guarantees. It references regulatory notices from the China Securities Regulatory Commission and confirms no violations as of December 31, 2021. The document is short (391 characters) and serves as a formal attestation or certification rather than a full audit or financial report. It does not contain financial statements or detailed audit results but is a regulatory compliance statement. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance-related announcement and independent opinion rather than a full Audit Report or Annual Report.
2022-03-09 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2021年度内部控制评价报告" which translates to "2021 Internal Control Evaluation Report". It is a detailed report on the company's internal control evaluation for the fiscal year ending December 31, 2021. The content includes evaluation conclusions, scope, methodology, internal control deficiencies, and corrective actions. It is issued by the company's board of directors and includes detailed internal control information, risk assessments, and compliance with regulatory standards. The document is lengthy (over 12,000 characters) and contains substantive content rather than just an announcement or certification. It is not an annual report (10-K), audit report (AR), or earnings release (ER), but specifically focuses on internal control evaluation, which aligns with the category of Audit Report / Information (AR). This category includes standalone audit reports and internal control evaluation results. Therefore, the document fits best under the Audit Report / Information (AR) classification with high confidence. FY 2021
2022-03-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.